Vicinitas Therapeutics (San Francisco, US) is developing the Deubiquitinase Targeting Chimera (DUBTAC) platform to therapeutically stabilize aberrantly degraded proteins in genetic diseases and cancer. — vicinitastx.com
Location: United States, California, South San Francisco
Investors 1
| Date | Name | Website |
| - | Droia Onco... | droiaventu... |
Mentions in press and media 1
| Date | Title | Description |
| 28.07.2022 | Vicinitas Therapeutics Raises $65M in Series A Financing | Vicinitas Therapeutics, a South San Francisco, CA-based biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, launched with $65m in Series A fina... |